MDX

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

Retrieved on: 
Wednesday, February 28, 2024
Medical Devices, Health, Other Science, Research, Science, Biotechnology, Acquisition, Hospital, Infection, Cystic fibrosis, Microbiology, MALDI, Mycobacterium, MDX, Fungal infection, PAI Partners, PAI, COVID, BRKR, Tuberculosis, Hand, Corporation, PCR, HIV, IVD, Partnership

This put option has now been exercised, and the parties have entered into a binding share purchase agreement.

Key Points: 
  • This put option has now been exercised, and the parties have entered into a binding share purchase agreement.
  • ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products.
  • Establishing this unique business within Bruker - a well-respected global life-science tools and specialty diagnostics company - provides an exciting opportunity to further grow our molecular diagnostics, microbiology and biomedical systems portfolios.
  • Upon closing, ELITech is expected to be a stand-alone business within Bruker’s Microbiology and Infection Diagnostics division, as a part of the Bruker CALID Group.

Global Molecular Diagnostics Market for Infectious Disease Analysis and Executive Guides 2023-2027: Assessing the Growing Demand for Rapid Diagnostic Solutions in Various Healthcare Settings - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 13, 2024
Biotechnology, Health, Health Technology, Other Science, Medical Devices, Research, Infectious Diseases, Hospitals, Genetics, Science, COVID-19, Analysis, Infection, Drug resistance, Nucleic acid, Blood, MDX, Country, Syndrome, Genomics, Diagnosis, Vertically transmitted infection, Molecular diagnostics, Pharmaceutical industry

The global market for molecular diagnostics (MDx) in infectious diseases is analyzed across various dimensions in this report.

Key Points: 
  • The global market for molecular diagnostics (MDx) in infectious diseases is analyzed across various dimensions in this report.
  • It begins with an overview of the global market by country, providing insights into regional trends and dynamics.
  • The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth.
  • A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe.

Microbix Unveils Test Control for Gastric Ulcer Disease Pathogen

Retrieved on: 
Tuesday, February 6, 2024
Poster, Product management, OTCQX, QAP, Tropical ulcer, Bacteria, MDX, Ulcer, Diagnosis, Temperature, EQA, Laboratory, TSX, Nobel Prize, QMS, Stomach, Infection, RUO, Accreditation, Helicobacter pylori, Medical device

H. pylori infection was discovered to be the cause of stomach (gastric) ulcers in the 1980’s, in what became a Nobel Prize winning health discovery.

Key Points: 
  • H. pylori infection was discovered to be the cause of stomach (gastric) ulcers in the 1980’s, in what became a Nobel Prize winning health discovery.
  • It is difficult to culture this pathogen, leading to the use of MDx methods for rapid diagnosis.
  • It is sponsored by Labquality Oy, a well-established Scandinavian clinical-lab proficiency and accreditation authority that is a Microbix customer and collaborator (https://www.labquality.com).
  • These H. pylori QAPs are now being made available on a research-use-only (RUO) basis from Microbix as part of its PROCEEDx®FLOQ® catalogue of products.

Three midsize luxury SUVs excel in back seat protection

Retrieved on: 
Thursday, December 14, 2023
IIHS, Injury, BMW, Shoulder, Volvo, XT6, Risk, Death, Acura, FEC, Research, Mercedes-Benz, Aircraft pilot, Lexus, Cadillac, Crash, MDX, Education, Head, Insurance, BMW X3, RX, XC60, Head Injuries, Lincoln Aviator, Thigh, Child, Human, Audi Q5, Safety, Torso, Hertz, SUV, Neck, Lexus RX

“It’s encouraging that more than half of the 2024 midsize luxury SUVs we tested performed well in our updated moderate overlap front crash test,” IIHS President David Harkey said.

Key Points: 
  • “It’s encouraging that more than half of the 2024 midsize luxury SUVs we tested performed well in our updated moderate overlap front crash test,” IIHS President David Harkey said.
  • Rather, the front seat has become safer because of improved airbags and advanced seat belts that are rarely available in back.
  • IIHS researchers also developed new metrics that focus on the injuries most frequently seen in back seat passengers.
  • All eight SUVs provided excellent protection in the front seat.

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
OTS, SOD1, UTRN, Heart, RNA, BMD, Myopathy, CNS, RNAa, SaRNA, Mouse, MDX, ALS, Duchenne muscular dystrophy, Lead, SCAD, Gene, DMD, Oligonucleotide, Therapy, Patient, Small RNA, Mutation, Vaccine

JIANGSU, China, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a clinical stage biopharmaceutical company founded by the pioneers in RNA activation (RNAa), presented recent preclinical results at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

Key Points: 
  • JIANGSU, China, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a clinical stage biopharmaceutical company founded by the pioneers in RNA activation (RNAa), presented recent preclinical results at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
  • RNAa uses short duplex RNA known as saRNA to target and ‘turn up’ transcription of endogenous genes leading to restoration of their protein function.
  • "We are very excited about the preclinical results of our utrophin activating saRNA and believe that our approach could represent an ideal therapeutic strategy that benefits all DMD and BMD patients," said Long-Cheng Li, CEO of Ractigen Therapeutics.
  • The SCADTM platform has propelled Ractigen’s leading RNA program to the clinic for the treatment of ALS patients with SOD1 mutation.

agilon health Announces Sale of MDX Hawaii

Retrieved on: 
Wednesday, November 1, 2023
Health, Hospitals, Health Technology, Practice Management, Managed Care, General Health, Physician, MDX, Geography, Sale, Patient, NYSE, Partnership, ACO, Medicare, Health insurance

agilon health (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it has sold MDX Hawaii, a wholly owned subsidiary, and its related operations to a private buyer.

Key Points: 
  • agilon health (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it has sold MDX Hawaii, a wholly owned subsidiary, and its related operations to a private buyer.
  • We are thankful to the entire MDX Hawaii team for their contributions to agilon health over the past seven years.”
    Acquired by agilon in 2016, MDX Hawaii is a provider network supporting approximately 600 physicians with fully-delegated risk contracts and management services organization capabilities, including claims processing and utilization management.
  • Management believes the sale of MDX Hawaii will allow agilon to focus on the company’s core partner markets in the continental United States.
  • The sale of MDX Hawaii and its related operations closed on Tuesday, October 31.

Microbix QAPs Supporting HPV Testing in Ireland

Retrieved on: 
Friday, October 27, 2023
System, Cervical cancer, Thorpe Coombe Hospital, MDX, OTCQX, HPV, Business development, QAP (Colombia), Senior, Republic, MSC, Immune system, Cancer, Human papillomavirus infection, Republic of Ireland, Medical device, Roche, Woman, Marketing, TSX, Infection, Vaccine, EU

MISSISSAUGA, Ontario, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its quality assessment products (“QAPs™”) are supporting a testing program for Human Papilloma Virus (“HPV”) using molecular diagnostic (“MDx”) technology at Dublin’s The Coombe Hospital, in the Republic of Ireland, an EU member-state.

Key Points: 
  • MISSISSAUGA, Ontario, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its quality assessment products (“QAPs™”) are supporting a testing program for Human Papilloma Virus (“HPV”) using molecular diagnostic (“MDx”) technology at Dublin’s The Coombe Hospital, in the Republic of Ireland, an EU member-state.
  • Dr. Lisa Tang, Head of Sales and Marketing of MSC commented, “We are pleased to support this important women’s health initiative with Microbix’s HPV QAPs.
  • We now look forward to the roll-out of MDx-based cervical cancer screening throughout the Republic of Ireland.”
    An initial purchase order for HPV-directed QAPs has been received by Microbix and it is expected that recurring QAPs sales into Ireland will become routine.
  • Phil Casselli, Senior Vice President of Sales and Business Development of Microbix also commented, “Ireland provides an example of Microbix’s technological leadership by way of our HPV quality controls being selected to support another national HPV screening program.

Neu REFIX β-glucan reduces muscle fibrosis in Duchenne muscular dystrophy MDX mice, in joint research with Dr. Yoshitsugu Aoki, NCNP, Tokyo, Japan.

Retrieved on: 
Tuesday, October 17, 2023
Science, Biotechnology, Research, Health, Hospitals, Genetics, Vitamins, Supplements, Clinical Trials, Molecular Therapy, Congress, Multimedia, Death, Plasma, Beta-glucan, National Center for Health Research, Scientific Reports, Inflammation, Trial of the century, DMD, Safety, NSAA, Disease, Pulmonary fibrosis, Patient, Allergen, Nature, Heart failure, Head, Neurology, Cardiac fibrosis, Clinical trial, MDX, Mouse, Duchenne muscular dystrophy, Pathology, Fibrosis, Multisystemic smooth muscle dysfunction syndrome, Myositis, MRC, Dietary supplement, Pharmaceutical industry, Psychiatry

This research was undertaken jointly with the team of Dr Yoshitsugu Aoki , Head, Dept.

Key Points: 
  • This research was undertaken jointly with the team of Dr Yoshitsugu Aoki , Head, Dept.
  • of Molecular Therapy, National Center for Neurology and Psychiatry (NCNP), Tokyo, Japan, a pioneer in developing solutions to DMD such as exon skipping therapy .
  • The findings published in Scientific Reports, a publication by Nature portfolio also reported a reduction in muscle inflammation, which precedes fibrosis and muscle dysfunction, leading gradually to respiratory muscle failure followed by lung dysfunction, cardiac fibrosis, heart failure and premature death.
  • With additional experiments in MDX mice underway , as more data evolves, that may be value adding to recommend Neu REFIX β-glucan to DMD patients, said Dr Yoshitsugu Aoki.

ProLabs to Showcase OpenZR+ and Fiber Connectivity Solutions at SCTE Cable-Tec Expo 2023

Retrieved on: 
Monday, October 16, 2023
DWDM, MPO, ARIA, LC, HDM, MSA, Temperature, QSFP, Colorado Convention Center, MDX, Microducts, SCTE, Bidirectional text, Internet service provider, Video game, Printed circuit board

ProLabs offers service provider networks solutions to the challenges of reducing bottlenecks throughout the network—from the core to the access network.

Key Points: 
  • ProLabs offers service provider networks solutions to the challenges of reducing bottlenecks throughout the network—from the core to the access network.
  • At Cable-Tec Expo 2023, ProLabs will showcase its latest advancements to support this evolution to faster, further fiber communications:
    OpenZR+—ProLabs has a complete complement of OpenZR+ coherent 400G pluggable transceivers that increase capacity over long-haul and metro networks directly from an Ethernet host.
  • Fiber Connectivity—ProLabs' line of ARIA fiber connectivity solutions features products that support greater densities for growing fiber connections in the data center as well as the outside plant.
  • Visit ProLabs in booth 1207 at Cable-Tec Expo 2023 to see the latest innovations.

MDX 2023: A CELEBRATION OF MALAYSIA'S DIGITAL ECONOMY

Retrieved on: 
Tuesday, September 19, 2023
The Digital Hub, Heart, MDX, Digital, Brace, ASEAN, MD, Film industry, Creative industries

KUALA LUMPUR, Malaysia, Sept. 19, 2023 /PRNewswire/ -- Embark on a captivating journey through the remarkable achievements of Malaysia Digital Economy Corporation (MDEC), as it continues to drive the country's digital economy forward with the ground-breaking and visionary Malaysia Digital (MD) national strategic initiative.

Key Points: 
  • KUALA LUMPUR, Malaysia, Sept. 19, 2023 /PRNewswire/ -- Embark on a captivating journey through the remarkable achievements of Malaysia Digital Economy Corporation (MDEC), as it continues to drive the country's digital economy forward with the ground-breaking and visionary Malaysia Digital (MD) national strategic initiative.
  • Brace yourself for the inaugural prestigious Malaysia Digital Expo 2023 (MDX 2023), where innovations and collaborations take centre stage.
  • From nationwide auxiliary events to conferences, exhibitions, launches, and industry awards dinners, MDX 2023 encapsulates the entire spectrum of technological evolution.
  • MDX 2023 supports the nurturing of local talent and provides visibility for tech companies to become Malaysian champions, bringing Malaysia's digital economy to greater heights.